This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Mannatech Applauds Cover Story Of The Economist: Microbes Maketh Man

Stocks in this article: MTEX

Mannatech, Incorporated (NASDAQ: MTEX), the leading innovator and provider of naturally sourced supplements based on Real Food Technology® solutions, announced today that it applauds the cover story of the August 18 th edition of The Economist, which introduced its readers to the human microbiome—the roughly 100 trillion bacteria that populate our bodies, inside and out. According to “Microbes Maketh Man,” the composition and behavior of bacteria in the gut is critically important for human health.

“At Mannatech, we have known for quite some time that the gut is fundamentally important for one’s overall wellness,” commented Dr. Rob Sinnott, CEO and Chief Science Officer at Mannatech. “In fact, we’ve been leading innovators in the design and testing of health products that positively influence the human microbiome. I’m excited to see this important area of scientific research get the attention it deserves by one of the most widely read and influential weekly publications in the world. It’s a surprising departure from the journal’s typical politics- or economics-focused cover story.”

Mannatech‘s interest in the ability of the gut to influence overall health increased in 2005, when the prestigious journal Science devoted much of an issue to “The Gut, Inner Tube of Life.” At that time, Mannatech knew that many people who consumed their glyconutritional supplements ( Ambrotose® products) experienced wide-ranging, powerful benefits, some of which were enhanced digestive health.* However, little was known about what happens to dietary glycans in the gut, and how their intake shapes gut bacterial populations, gut health and overall health. Given these scientific gaps, Mannatech’s Research and Development team began to devote significant scientific muscle to get some answers.

Since then, Mannatech scientists have presented research at scientific meetings and published studies in peer-reviewed journals. These studies have reported basic glycan chemistry data, 1, 2, 3 in vitro data reporting the molecular weight of glycan polymers following digestion by human gut bacteria, 4 and prebiotic effects—including the possibility of enhancing species belonging to Bacteroidetes, a group of bacteria associated with weight management. 5*

Preclinical research indicates that oral intake of Ambrotose products can impact the colon, including exerting positive effects on colonic cell gene expression. 6 Mannatech scientists have also published literature reviews reporting the impact of dietary glycans on the immune system 7 and the brain 8—areas of particular interest to Mannatech because of studies indicating that intake of glyconutrients can benefit the gut and the immune system.*

“We are proud to be a leader in developing innovative dietary supplements that positively impact the gut microbiome based on science derived from an understanding of how glycans impact the gut: a small contribution to the extraordinary advances in microbiome research,” said Dr. Sinnott.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs